RxDoctor Payments Data

Bruce Fleishman, MD

Cardiovascular Disease · Grove City, OHNPI 1508812769

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 73 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Circulation Inc$304
  • Novartis$253
  • Silk Road Medical, Inc.$100
  • Novo Nordisk$91
  • Boston Scientific$88
  • Pfizer$78
  • plus $417 from 12 others

What the payments were for

  • Food & beverage$1,31999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,332 in reported general payments places this provider in the 45th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$145,415
Medicare patients
1,908
Services billed
2,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban475$510,115
XareltoRivaroxaban190$247,253
EntrestoSacubitril/Valsartan106$124,307
Repatha SureclickEvolocumab40$32,579
FarxigaDapagliflozin Propanediol33$32,046
JardianceEmpagliflozin27$17,872
Metoprolol Succinate733$9,074
Praluent PenAlirocumab11$8,087
Diltiazem 24hr Er (Cd)Diltiazem Hcl146$6,496
Prasugrel Hcl74$6,033
Atorvastatin Calcium520$4,751
Ezetimibe113$4,457
Ranolazine ErRanolazine43$3,654
Amiodarone Hcl145$3,207
Flecainide Acetate73$2,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$510,115475 claims
Johnson & JohnsonXarelto$29$247,253190 claims
NovartisEntresto$253$124,307106 claims
AstraZenecaFarxiga$75$32,04633 claims
Boehringer IngelheimJardiance, Pradaxa$42$20,35140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Grove City

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →